Natural killer cell engineering for cellular therapy of cancer

Tissue Antigens

Volumn 78, Issue 6, 2011, Pages 409-415

  Shook, D R ^a   Campana, D ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cell therapy; Chimeric receptors; Immunotherapy; Natural killer cells

Indexed keywords

CD137 ANTIGEN; INTERLEUKIN 15;

CANCER THERAPY; CELL EXPANSION; CELL THERAPY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; LEUKEMIA CELL; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW;

4-1BB LIGAND; CELL ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 81155124466     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01796.x     Document Type: Review

References (60)

1. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002: 2: 850-61.
2. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006: 20: 123-37.
3. Caligiuri MA. Human natural killer cells. Blood 2008: 112: 461-9.
4. Vivier E, Raulet DH, Moretta A et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011: 331: 44-9.
5. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008: 10: 775-83.
6. Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. J Immunother 2008: 31: 685-92.
7. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003: 101: 3052-7.
8. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A 108: 728-32.
9. Jaleco AC, Blom B, Res P et al. Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells. J Immunol 1997: 159: 694-702.
10. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995: 85: 2654-70.
11. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005: 86: 209-39.
12. Lanier LL. NK cell recognition. Annu Rev Immunol 2005: 23: 225-74.
13. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004: 23: 255-9.
14. Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005: 436: 709-13.
15. Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol 2010: 651: 61-77.
16. Alici E, Sutlu T, Sirac Dilber M. Retroviral gene transfer into primary human natural killer cells. Methods Mol Biol 2009: 506: 127-37.
17. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008: 8: 713-25.
18. Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003: 5: 259-72.
19. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984: 160: 1147-69.
20. London L, Perussia B, Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol 1986: 137: 3845-54.
21. Alici E, Sutlu T, Bjorkstrand B et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008: 111: 3155-62.
22. Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997: 99: 937-43.
23. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005: 106: 376-83.
24. Robertson MJ, Manley TJ, Donahue C, Levine H, Ritz J. Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol 1993: 150: 1705-14.
25. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992: 148: 2429-36.
26. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992: 80: 2221-9.
27. Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun 1996: 15: 213-26.
28. Luhm J, Brand JM, Koritke P, Hoppner M, Kirchner H, Frohn C. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002: 11: 651-7.
29. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol 1991: 135: 454-70.
30. Berg M, Lundqvist A, McCoy P Jr et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009: 11: 341-55.
31. Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol 2004: 32: 614-21.
32. Musso T, Calosso L, Zucca M et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 1999: 93: 3531-9.
33. Kobayashi H, Dubois S, Sato N et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005: 105: 721-7.
34. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998: 190: 167-72.
35. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009: 69: 4010-7.
36. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol 2009: 145: 606-13.
37. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005: 105: 3051-7.
38. Rubnitz JE, Inaba H, Ribeiro RC et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010: 28: 955-9.
39. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010: 107: 11906-11.
40. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010: 16: 392-8.
41. Nagashima S, Mailliard R, Kashii Y et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998: 91: 3850-61.
42. Zhang J, Sun R, Wei H, Tian Z. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 2004: 89: 338-47.
43. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010: 16: 3901-9.
44. Borrego F, Kabat J, Kim DK et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002: 38: 637-60.
45. Romagne F, Andre P, Spee P et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009: 114: 2667-77.
46. Figueiredo C, Seltsam A, Blasczyk R. Permanent silencing of NKG2A expression for cell-based therapeutics. J Mol Med 2009: 87: 199-210.
47. Imai C, Campana D. Genetic modification of T cells for cancer therapy. J Biol Regul Homeost Agents 2004: 18: 62-71.
48. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011: 365: 725-33.
49. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 2011: 3: 95ra73.
50. Muller T, Uherek C, Maki G et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008: 57: 411-23.
51. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 2008: 181: 3449-55.
52. Altvater B, Landmeier S, Pscherer S et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009: 15: 4857-66.
53. Kruschinski A, Moosmann A, Poschke I et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 2008: 105: 17481-6.
54. Savani BN, Mielke S, Adams S et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007: 21: 2145-52.
55. Leung W, Iyengar R, Turner V et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004: 172: 644-50.
56. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011: 117: 764-71.
57. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007: 97: 539-42.
58. Venstrom JM, Zheng J, Noor N et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009: 15: 7330-4.
59. Li L, Liu LN, Feller S et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2010: 17: 147-54.
60. Boyiadzis M, Memon S, Carson J et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant 2008: 14: 290-300.